Home / Market News / $ROG.SW

$ROG.SW news and market catalysts

The 5 most recent market catalysts affecting $ROG.SW, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 1 high impact 4 bullish 0 bearish Pharmaceuticals
Sep 23, 2026 Corporate Catalyst Bullish Impact 75
Roche's Sefaxersen Meets Primary Endpoint In Phase III IMAgINATION Study, Significantly Reduces Proteinuria Versus Placebo At 37 Weeks In IgA Nephropathy Patients
Roche's sefaxersen successfully met its primary endpoint in the Phase III IMAgINATION study, showing statistically significant and clinically meaningful reductions in proteinuria i…
Sep 22, 2026 Corporate Catalyst Bullish Impact 85
Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients
Roche announced exceptionally strong Phase II trial results for enicepatide, a drug targeting Type 2 Diabetes (T2D) and obesity. The drug achieved significant HbA1c reductions (up …
Sep 18, 2026 Corporate Catalyst Neutral Impact 65
Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis
Roche's Ocrevus has received a positive opinion from the EMA's CHMP for pediatric relapsing multiple sclerosis, following its FDA approval in May 2026. This is a significant develo…
Sep 14, 2026 Corporate Catalyst Bullish Impact 75
Reported Saturday, Roche's B7-H3-Targeted ADC Tam-Peli Meets Primary Endpoint In Phase III TAISHAN-302 Trial, China's NMPA Accepts New Drug Application For Filing
Roche's Tam-Peli, an antibody-drug conjugate, met its primary endpoint in a Phase III trial in China for relapsed small-cell lung cancer, showing a 54% reduction in death risk and …
Jul 23, 2026 Corporate Catalyst Bullish Impact 75
Roche Reports H1 2026 Revenue Of CHF 30.4B, Up 6% At CER But Down 2% In CHF, As Core EPS Rises 9% At CER To CHF 10.85 From CHF 11.08
This headline is a significant corporate catalyst for Roche, as it provides a detailed look into their recent financial performance. The divergence between constant exchange rate (…
 Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.